header
February 19, 2018

In This Issue
IN THE SPOTLIGHT
AMA Advocacy Conference Highlights High Drug Costs, Regulatory Relief and Coverage Concerns
MMA Board to Address Several Critical Issues at Annual President's Retreat in March
Use EMR System Defaults to Reduce Opioid Prescribing
CMS Projects Health Care Spending to Increase Significantly in Next Decade
Purdue Pharma Announces Cessation of Marketing Oxycontin to Prescribers
Health Access Network Names New Chief Executive Officer
Notes from the American Medical Association
3 Ways to Maximize Employer Diabetes Prevention Tools for Your Patients
128TH MAINE LEGISLATURE
Legislative Call This Tuesday, February 20th
Legislative Report: "Conversion therapy" and More
UPCOMING EVENTS
Healthcare Suicide Prevention Protocol Development Training - half day workshop - March 2
28th Annual Winter Conference - Contemporary Topics in Orthopedics - March 16-18
QC2018: Building Communities of Practice through Innovation - Wednesday, April 4, 2018
MMA and Jackson Laboratory Seeking Volunteers to Assist with 2018 Maine Cancer Genomics Initiative Forum
New Free CME on Alzheimer's Risk, Detection, and Management
Peer Navigation Program from Facing Our Risk of Cancer Empowered (FORCE)
Online Learning Opportunities Offering CME Credits - from the Northern New England Practice Transformation Network
HEALTHCARE EMPLOYMENT OPPORTUNITIES
Associate Director/Director of Compliance, Privacy, Risk and Legal Affairs for Penobscot Community Health Care in Bangor, Maine
MD/DO - Lewiston, ME
Chief Executive Officer CEO at Greater Portland Health
Outpatient Internal Medicine Physician Bangor, Maine
Relocate to Beautiful Southwestern Maine - Medical Director/Family Practice Physician
Clinical Cardiology Opportunity
Outpatient Only - Internal Medicine with Loan Repayment & Sign-on Bonus
Opportunities at the VA for Volunteer Physicians

 
Search Back Issues





 



Follow Us:
Purdue Pharma Announces Cessation of Marketing Oxycontin to Prescribers

The privately held company based in Stamford, Ct. made the announcement following criticism of the way that opioid manufacturers market controlled substances.  The company's remaining sales force of 200 detailers will now focus on Symproic, a drug for treating opioid-induced constipation and other potential non-opioid products.
 
Purdue and other manufacturers have been fighting lawsuits by state, counties and cities that have alleged that the companies deceptively marketed their opioid products. Purdue and three executives pleaded guilty in 2007 to federal charges related to the misbranding of oxycontin and paid $634.5 million to settle charges brought about by a U.S. Justice Department investigation.  Purdue also reached a $19.5 million settlement that same year with 26 states and the District of Columbia.  It agreed in 2015 to pay $24 million to resolve a lawsuit in Kentucky.
 
In an interview with Maine Public radio one week ago, MMA President Robert Schlager, M.D. noted that while the action by the company was a good step, it was one that should have taken place many years ago and expressed concern that the company has arrangements with companies marketing their product internationally and that those companies are allegedly using the same marketing tactics as were used in this country.  Family physician Noah Nesin, M.D. of Bangor in the same story noted that the company begin this marketing over 20 years ago and that as a result hundreds of thousands of patients developed opioid use disorder and many have been victims of overdose deaths.  
 


 
 
< Previous Article | Next Article >

[ return to top ]

To ensure delivery of Maine Medicine Weekly Update,
please add 'info@mainemed.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm


Unsubscribe here

For more information or to contact us directly, please visit www.mainemed.com | ©